Astex Pharma (ASTX) Reiterated Buy at RBC (Street Insider.com)
RBC Capital reiterated an Outperform rating on Astex Pharmaceuticals, Inc. (NASDAQ:ASTX) with a price target of $9.00. Comments follow topline results from the ongoing phase 2 of SGI-110 in patients with AML and MDS. Analyst Michael Yee continues to believe the drug is undervalued. In his opinion, the SGI-110 looks much more active than older Dacogen (Eisai).
Zale Corporation : Zale Returns to Full Year Profitability (4- Traders)
Zale Corporation (NYSE:ZLC) today reported its financial results for the fourth quarter and full year ended July 31, 2013. “We are pleased to report another solid quarter with a 5.6 percent comp and significant improvement to margins. Importantly, for the year we achieved a significant milestone by delivering our highest net income in six years,” commented Chief Executive Officer Theo Killion. “We intend to build on this momentum as we focus on driving profitable top-line growth and long-term shareholder value.”
UPDATE 2-Joy Global warns on revenue as coal glut hits orders (Reuters)
Joy Global Inc. (NYSE:JOY) a maker of mining equipment, reported a 36 percent slide in quarterly orders and warned of sharply lower revenue for a further year as coal producers cut back capital spending in the face of a supply glut and low prices. Joy Global Inc. (NYSE:JOY), which derives two-thirds of its revenue from sales to coal miners, said it would increase cost cutting to offset the slide in orders.
Astex Pharmaceuticals Inc : Astex Pharmaceuticals Announces Topline Results of SGI-110 AML Phase 2 Study (4-Traders)
Astex Pharmaceuticals, Inc. (NASDAQ:ASTX) today announced topline results from the ongoing phase 2 of SGI-110 in patients with AML and MDS. The Phase 2 study is a randomized study of SGI-110 given either as 60 or 90 mg/m2 daily for 5 days in a 28-day course. As of end of June data cutoff, 67 AML patients had a minimum follow up of 3 months (50 patients representing the complete cohort of relapsed/refractory AML, and 17 patients in the treatment-naive elderly AML not suitable for induction chemotherapy cohort). The primary endpoint is overall remission rate (Complete Remission or CR; Complete Remission with Incomplete hematologic recovery or CRi/CRp). There were 8 remissions in relapsed/refractory AML and 9 remissions in treatment-naive elderly AML for an overall complete remission rate (CR, CRi/CRp) of 17/67 or 25%. The detailed results have been submitted for presentation to the American Society of Hematology (ASH) meeting to be held later this year during December 7-10 in New Orleans, LA.
IBEROSTAR Hotels & Resorts And Zale Corporation Help Contest Winner (Hospitality Industry)
IBEROSTAR Hotels & Resorts and Zale Corporation (NYSE:ZLC) recently teamed up to help the winner of their “The Most Epic Proposal Ever” contest pop the question in a spectacle of truly epic proportions valued at over $65,000 USD. Following a search across America for the most over-the-top, elaborate proposal idea, IBEROSTAR and Zale Corporation (NYSE:ZLC) selected winner John Noojin of Lincoln, Nebraska for his heartwarming love story about girlfriend Kylie Hauer and his creative plan to propose at the opulent IBEROSTAR Grand Hotel Paraiso in Riviera Maya, Mexico.
Cramer’s JOY-ful Mad Dash (CNBC)